Development asset linked to Chinese PLA General in public FDA and regional records.
pharma · Hepatocellular Carcinoma · Liver Cancer
Chinese PLA General
Chinese PLA General Hospital
Chinese PLA General drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 4
- Drugs
- 9
- Patents
- 0
Chinese PLA General pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Chinese PLA General drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Chinese PLA General in public FDA and regional records.
-
Development asset linked to Chinese PLA General in public FDA and regional records.
-
Development asset linked to Chinese PLA General in public FDA and regional records.
-
Development asset linked to Chinese PLA General in public FDA and regional records.
-
Development asset linked to Chinese PLA General in public FDA and regional records.
-
Development asset linked to Chinese PLA General in public FDA and regional records. Molecular target: Thymidylate synthase.
- Target
- Thymidylate synthase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Chinese PLA General in public FDA and regional records.
-
Development asset linked to Chinese PLA General in public FDA and regional records.